High-sensitivity C-reactive protein and mean platelet volume as predictive values after percutaneous coronary intervention for long-term clinical outcomes

Abstract

This study was designed to establish the relationship of high-sensitivity C-reactive protein (hsCRP) and mean platelet volume (MPV) with the development of adverse outcomes after percutaneous coronary intervention (PCI). hsCRP levels and MPV were analysed in 372 patients who underwent PCI, with the primary endpoint as major adverse cardiac and cerebrovascular events (MACCE): a composite of cardiac death, myocardial infarction (MI), target vessel revascularization (TVR), ischemic stroke and stent thrombosis. During the follow-up period (mean, 25.8 months), there were 21 cardiac deaths, 10 MIs including four stent thrombosis events, seven ischemic strokes and 29 TVRs. The hsCRP cut-off level was set at 0.31 mg/dl using the receiver operating characteristic curve to differentiate between the groups with and without MACCE. The MPV cut-off level was set at 8.00 fl by the receiver operating characteristic curve to differentiate between the groups with and without MACCE. A Kaplan-Meier analysis revealed that the high hsCRP group (≥0.31 mg/dl) had a significantly higher cardiac death and MACCE rate than the low hsCRP group (<0.31 mg/dl), and the high MPV group (>8.00 fl) had a significantly higher cardiac death and MACCE rate than the low MPV group (≤8.00 fl). Furthermore, the high hsCRP and MPV groups were significantly associated with an increased risk of MACCE. These results show that hsCRP and MPV are predictive markers after PCI for MACCE; they are also additively associated with a higher risk of MACCE.

Relationship between White Blood Count to Mean Platelet Volume Ratio and Clinical Outcomes and Severity of Coronary Artery Disease in Patients Undergoing Primary Percutaneous Coronary Intervention

“…Comorbid factors, LVEF, medical treatment approaches, results, and complications of interventional treatments can affect treatment results and MACE regardless of the level of inflammation. Similarly to our study, due to the abovementioned adverse factors, in previous studies examining the relationship between inflammation parameters and MACE, the specificity rates are generally lower than the sensitivity rates [ 32 , 33 ]. In risky clinical situations such as STEMI, markers that do not require additional costs, such as WMR, have a high sensitivity in determining risk and may be more valuable in clinical risk classification and treatment planning.…”

Association between multimorbidity and mean platelet volume in diabetic patients with acute myocardial infarction

“…Elevated MPV along with increased inflammation biomarkers (e.g., C-reactive [CRP], interleukin-6 [IL-6] among other) were reported in many conditions which are characterized by low-grade inflammation including ischemic stroke [ 49 ], utricaria [ 50 ], postoperative atrial fibrillation [ 51 ], adverse outcomes following percutaneous coronary intervention [ 52 ], myocardial infarction [ 53 ], urinary tract infection [ 54 ], exacerbations of COPD [ 55 ], hypertension [ 56 ], rheumatoid arthritis (RA) [ 57 ], osteoarthritis [ 58 ], and pneumonia [ 59 ].…”

Reliability of C-reactive protein as a predictor of early neurological deficit in acute ischemic stroke: is it only to be blamed? a retrospective observational study

“…25 addition, it can also be used for the prediction of future development of atherosclerotic diseases including stroke and cardiovascular disease. [23][24][25] But wide variation in the results between this study and other studies could also be due to different definitions of END, time scale of assessment of acute stroke and varied process of selection of patients.…”

“…23 Moon AR et al, found the association of hs (high sensitivity) CRP and Mean Platlet Volume (MPV) as one of the predictors of long term clinical outcomes in post Percutaneous Transluminal Coronory Angioplasty (PTCA) patients. 24 Jimenez MC et al, also found significant association between hs CRP and stroke severity in hypertensive patients. 25 addition, it can also be used for the prediction of future development of atherosclerotic diseases including stroke and cardiovascular disease.…”